Metabolic & Weight Management
CagriSema
Combination cagrilintide/semaglutide studied for dual amylin and GLP-1 receptor signaling in weight research.
Dual-pathway appetite researchWeight-management studiesMetabolic marker research
How it works in the body
Brain
Stomach
Pancreas
Liver
Adipose Tissue
RESEARCH USE ONLYINVESTIGATIONAL COMPOUNDAvailable following assessmentREGENEXA ASSESSMENT
Vial concentration
CagriSema
5 mgThis is a clinician-reviewed research peptide. Pricing is provided as part of an approved, personalized plan after your assessment is reviewed.
Not sure where to start?
Discover what may fit your goals — a short, personalized Regenexa Assessment.
Take Your Assessment →- 🔒 Secure & encrypted checkout
- 📦 Fast, discreet worldwide shipping
- 🧪 Pharmaceutical-grade quality
- 🔬 Research use only
Not sure where to start? Discover what may fit your goals — a short, personalized Regenexa Assessment.Take Your Assessment →
Fixed-ratio co-formulation pairing amylin-receptor agonism (satiety, gastric emptying) with GLP-1-receptor agonism (appetite, glycemic control) for additive weight effect.
Receptors
Amylin receptorGLP-1 receptor
Half-life: Both components support once-weekly dosing (~7 days for cagrilintide, ~7 days for semaglutide).
Ask Regenexa AI about CagriSema
Get plain-language answers on mechanism, evidence and how it compares to other peptides — grounded in Regenexa's verified data.
“Is CagriSema stronger than semaglutide alone?”Ask Regenexa AI →Available following assessmentTake Assessment
GLP-3 R
Cagrilintide
Survodutide
Mazdutide